Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov;38(16):3193-3196.
doi: 10.1038/s41433-024-03220-z. Epub 2024 Jul 23.

Biosimilar ranibizumab (BS1) - early experience from Japan (BRIJ study)

Tomoko Ueda-Consolvo  1 , Masaaki Ishida  1 , Tomoko Nakamura  1 , Shuichiro Yanagisawa  1 , Kotaro Tsuboi  2 , Taku Wakabayashi  3 , Atsushi Hayashi  1 , Ashish Sharma  4 ; International Retina Biosimilar Study Group (Inter BIOS Group)
Collaborators, Affiliations

Biosimilar ranibizumab (BS1) - early experience from Japan (BRIJ study)

Tomoko Ueda-Consolvo et al. Eye (Lond). 2024 Nov.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Ashish Sharma: CONSULTANT: for Novartis, Allergan, Bayer and Intas. Tomoko Ueda-Consolvo Masaaki Ishida, Tomoko Nakamura, Shuichiro Yanagisawa, and Taku Wakabayashi: None.

References

    1. Sharma A, Kondo M, Iwahashi C, Parachuri N, Kumar N, Bandello F, et al. Approved biosimilar ranibizumab-a global update. Eye (Lond). 2023;37:200–2. - PMC - PubMed
    1. Sharma A, Holz FG, Regillo CD, Freund KB, Sarraf D, Khanani AM, et al. International Retina Biosimilar Study Group (Inter BIOS Group). Biosimilars for retinal diseases: United States-Europe awareness survey (Bio-USER - survey). Expert Opin Biol Ther. 2023;23:851–9. - PubMed
    1. Sharma S, Khan MA, Chaturvedi A, RE-ENACT Study Investigators Group. Real-Life clinical effectiveness of Razumab® (the world’s first biosimilar of ranibizumab) in retinal vein occlusion: a subgroup analysis of the pooled retrospective RE-ENACT study. Ophthalmologica. 2019;241:24–31. - PMC - PubMed
    1. Sharma S, Khan MA, Chaturvedi A, RE-ENACT Study Investigators Group. Real life clinical effectiveness of Razumab® (world’s first biosimilar ranibizumab) in wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion: A retrospective pooled analysis. Int J Oph thalmol Eye Res. 2018;6:368–73.
    1. ASRS. Efficacy and safety of biosimilars ranibizumab-nuna and ranibizumab eqrn in clinical use. (2023). https://www.ophthalmologytimes.com/view/asrs-2023-efficacy-and-safety-of....

LinkOut - more resources